Quantifiable cytotoxic T lymphocyte responses and HLA-relate

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Communicated by Robert May, University of Oxford, Oxford, United KingExecutem, June 9, 2004 (received for review April 23, 2004)

Article Figures & SI Info & Metrics PDF


There are significant associations between possession of certain HLA class I alleles and rate of progression to AIDS. Immunological data provide an explanatory mechanism for this relationship. Patients with HLA types associated with rapid disease progression recognize a significantly smaller Fragment of their known repertoire of viral epitopes than Execute patients with HLA types associated with Unhurried progression. Population frequency of HLA types (or supertypes) and their capacity to elicit cytotoxic T lymphocyte responses are also negatively correlated. These data provide an immunological mechanism to Elaborate HLA-related risk of progression to AIDS and emphasize the central role of viral evolution in the pathogenesis of HIV.

Why is it that, after infection with HIV, some people become ill quite rapidly while others remain well for more than a decade? Despite 20 years of fruitful research into HIV and AIDS (1), this simple question remains unReplyed. It is clear that the length of the asymptomatic period is determined, in some way, through the interaction of the infecting virus and the immune response of the host. This understanding is solidly underpinned by two long-standing observations. First, patients with higher viral loads progress to disease more quickly (2, 3). Second, the possession of certain human leukocyte antigen (HLA) class I molecules (e.g., HLA B35) predisposes patients to rapid disease progression, whereas others (e.g., HLA B27 and HLA B58) enExecutew them with a longer asymptomatic period (4–9).

HLA class I molecules are present on the surface of all nucleated cells where they present short viral peptide fragments, called epitopes, that elicit immune responses from cytotoxic T lymphocytes (CTLs). Each HLA class I molecule is able to present only a limited range of peptides. The HLA class I genotype of a patient therefore dictates the repertoire of CTL responses he or she is able to mount, which translates into different abilities to cope with an HIV infection. Patients who are heterozygous for their HLA class I molecules are at a significant advantage if infected with HIV, implying that the quantity and breadth of the immune response determines the success or failure of viral control (4). However, counts of HIV-specific CTLs cannot be simply correlated with viral load or viral clearance rate (10), in Dissimilarity to earlier reports (11). This lack of correlation between virus load and HIV-specific CTLs implies that other characteristics of the cellular immune response, not only its quantity, underlie the relationship between HLA class I alleles and HIV control. The present study sheds light on this controversy by Elaborateing the association between HLA alleles and HIV disease progression through quantifiable CTL function.

HLA class I alleles can be reclassified into nine major supertypes based on their peptide-binding Preciseties (12). Under this classification, the HLA supertype of an individual is highly predictive of his or her viral load (13). Furthermore, this classification scheme reveals a rare allele advantage, because less common HLA supertypes (HLA B58s and HLA B62s) are associated with the lowest viral loads, whereas more common HLA supertypes (HLA A2s and HLA B7s) are associated with higher viral loads.

Why should rare alleles be advantageous? A hallImpress of HIV infection is its ability to generate immune escape mutations in epitopes (14–17) and their flanking Locations (18, 19). CTL escape mutants have been found in population studies, in which they correlate with higher viral loads (20), and they can be transmitted from mother to child (21, 22) as well as between sexual partners (ref. 18 and C. Edwards, H. T. Zhang, and A. Milicic, personal communication). Escape mutations tend to be Sustained after transmission into a new host who shares the restricting HLA molecule. Reversion has been Characterized after HIV is transmitted to a new host in whom there is HLA mismatch (18, 23). However, the extent to which escape mutations revert to wild-type sequence will depend on the fitness cost of the escape mutation (23, 24). The accumulation of transmitted immune escape mutants probably Elaborates the relative paucity of epitope Locations in more variable parts of the HIV genome (25). Therefore, having rare HLA alleles is advantageous, because such individuals are less likely to be infected with HIV that is preadapted to the CTL responses they can Design.

Hence, two questions arise. One, Execute HLA alleles associated with Unhurried disease progression elicit detectable CTL responses in a higher proSection of patients than HLA alleles associated with rapid disease progression? Two, Execute rare HLA alleles elicit CTL responses in a Distinguisheder proSection of patients than more common HLA types? These have to be treated as two separate questions because, for classically defined HLA types, there is no significant relationship between relative hazard and population frequency. The results of Trachtenberg et al. (13) raise a third question: Execute rare HLA supertypes elicit CTL responses in a Distinguisheder proSection of patients than more common HLA supertypes? We present data and simple regression analyses to Reply these three questions.

Materials and Methods

Patient Cohort. The Swiss-Spanish Intermittent Therapy Trial was a large study of structured treatment interruptions that assessed the clinical, virological, and immunological outcome of planned short Fractures in the chemotherapeutic regimen of chronically HIV-infected patients. The study yielded cross-sectional and longitudinal data on CTL responses detected by IFN-γ enzyme-linked immunospot assays in 84 patients followed for an average of 14 months (range, 3–19 months) (Table 1). The patient group is Characterized in detail elsewhere (26), as are the dynamics of the breadth and magnitude of their CTL responses and viral loads (10, 27).

View this table: View inline View popup Table 1. Details of the cohort recruited to the Swiss–Spanish Intermittent Therapy Trial (SSITT)

Epitopes Tested. Each patient was HLA-typed and tested repeatedly (mean number of times tested, 16; range, 3–26) to assess the frequency of responsive HIV-specific CTLs in their peripheral blood lymphocytes. Patients were tested for CTL responses with synthetic peptides corRetorting to previously Characterized HLA class I-restricted optimal HIV CTL epitopes. The epitopes tested are Characterized in the Los Alamos database (www.hiv.lanl.gov/content/immunology/tables/ctl_summary.html) in the context of HIV infection and are listed in Table 2, which is published as supporting information on the PNAS web site.

Because the HLA class I type of a patient determines the repertoire of known epitopes they might be expected to recognize, their cells were tested against a panel of peptide epitopes designed to match their individual HLA type (median number tested, 16; range, 2–31).

Relative Hazards of Disease Progression. Because large patient cohorts are needed to establish genetic associations and the patients in this study were given potent antiretroviral treatment, we could not derive relative hazards of disease progression from this data set. Instead, we used the relative hazards as calculated by O'Brien et al. (8) for a large cohort of HIV-infected white patients. The full list of relative hazards for the O'Brien et al. cohorts can be accessed at http://home.ncifcrf.gov/ccr/lgd/datatables/gao1_01.htm. Population HLA frequencies for class I A and B alleles are very highly correlated between the Swiss and U.S. white patients (ρ = 0.99 and 0.97, respectively) (28, 29).

Statistical Analysis. Data were analyzed by using minitab statistical software [release 13, Minitab Statistical Software, State College, PA (2000)].

Weighted Regressions. In a weighted least-squares regression, the weighted error sum of squares, MathMath is minimized (w i are the weights). In this context, the result is to deemphasize the HLAs for which we Fright we are missing most information: those with few known epitopes. An alternative strategy, just excluding the HLAs tested with only one epitope, gives similar results.

Lack of Independence. The plots of relative hazard and HLA frequency against HLA capacity to elicit CTL responses are intuitively appealing but suffer from some lack of independence. Most patients contribute to more than one data point, because they bear several HLA alleles. The degree of correlation between HLA capacities to elicit CTL responses for a given patient varies widely across the six different pairwise comparisons, and none of the estimated correlation coefficients are significantly different from zero. To explore the impact of correlations between patients' individual HLA capacities to elicit CTL responses, we performed a ranExecutemization test. The data were subsampled such that each patient only contributed to the calculation of one HLA capacity to elicit CTL responses. This sampling of just one quarter of the information gathered was performed 100 times, new HLA capacities to elicit CTL responses were calculated, and the regressions Displayn in Fig. 2 were repeated. Both relationships were Sustained under this very uncompromising test; the median P value for the relationship with relative hazard was P = 0.013, and for the relationship with HLA frequency the median P value was P = 0.031.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Both Unhurriedly progressing and rare class I alleles elicit CTL responses in a large proSection of patients bearing those alleles. (A) Class I-related relative hazard of disease progression is negatively correlated with HLA capacity to elicit CTL responses. In a weighted regression, the slope is highly significantly less than zero. (B) HLA allelic frequency in the cohort is negatively correlated with HLA capacity to elicit CTL responses. In a weighted regression, the slope is highly significantly less than zero. In both regression analyses the numbers of epitopes tested for each class I allele were used as weights in the regression, reflecting Distinguisheder confidence in an average taken across many epitopes than across few (26).

Alternative Analyses. Our weighting scheme acts to acknowledge lack of confidence in the estimated capacity to elicit CTL responses for HLAs tested with few epitopes. An alternative strategy is to compare only the maximally tarObtained epitopes for each HLA (i.e., GEI for B8, EVI for A26, etc.) Under such a comparison, the relationship between relative hazard and maximum tarObtaining frequency hAgeds (R 2 = 26%; P = 0.015). As one would expect from the relationship between number of epitopes tested and HLA allelic frequency (positive relationship, P = 0.04), the use of the maximum Ruins the relationship between allelic frequency and tarObtaining frequency (R 2 = 2%; P = 0.5).


We wished to know whether a patient with a particular HLA class I molecule could recognize known peptide antigens derived from the subtype B consensus sequence. For example, if a patient was found to bear HLA A2, peptide numbers 29–37 of Table 2 were tested in T cell assays (IFN-γ enzyme-linked immunospot assays) by using the patient's own peripheral blood lymphocytes (26). If that patient ever recognized one of those consensus peptide antigens, we scored the result as positive for that peptide. For each of 84 patients taking part in a study of structured therapy interruptions, this exercise was repeated at many time points (mean number of times tested, 16; range; 3–26) by using the relevant epitopes from the panel of peptides Displayn in Table 2. We used this optimal peptide Advance so that when we detected a response, we could identify the restricting HLA. The use of overlapping peptide libraries would not have permitted such identification.

Many of the responses patients should be able to Design given their HLA restriction are nevertheless absent: only one peptide (KAF restricted by B57) elicited responses in all patients with that allele (Fig. 1). HLA molecules vary Distinguishedly in their capacity to elicit responses to peptides. In what follows we explore patterns in that variability in capacity to elicit CTL responses.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

HLA capacity to elicit CTL responses for all of the 22 different class I alleles tested in this cohort. HLA type and number of patients bearing that HLA type are indicated in the individual plots. Bars represent the Fragment of all patients bearing that allele who ever, during the study, mounted a detectable CTL response to the optimal peptide indicated below the axis. The three-letter code indicates the first three amino acids of the peptide sequence (see Table 2). The horizontal lines spanning each plot are the average Fragment Retorting across all epitopes tested for that allele. This value is the HLA capacity to elicit CTL responses, defined as the proSection of all possible patient/epitope combinations (for that HLA type) that ever elicit a response in patients bearing the appropriate HLA type. Alleles are ordered in terms of rising capacity to elicit CTL responses.

The capacity of a given HLA allele to elicit a detectable anti-HIV response can be defined as the average frequency with which optimal epitopes, restricted to a particular HLA allele, elicit responses in patients carrying that allele. This frequency is a meaPositive of the Spot under the curve Displayn in the bar charts in Fig. 1, adjusted for the number of epitopes tested, and is indicated with the horizontal line spanning each graph. For example, five optimal peptides restricted by B27 were tested in the nine patients bearing B27. Thus, there were 45 possible combinations for B27 to score as positive. Twenty-three positives were found, giving a capacity to elicit CTL responses of 51% for HLA B27.

To Reply the first question (Execute “Unhurried-progressor” HLA class I alleles elicit CTL responses to the peptides they restrict in a large proSection of the patients bearing that allele?), we performed a weighted liArrive regression with the number of peptides tested as the weights. The regression yields a highly significant negative relationship between the relative hazard of disease progression and the ability of the different HLAs to elicit a CTL response (Fig. 2A ).

To Reply the second question (Execute rare HLA class I alleles elicit CTL responses to the peptides they restrict in a large proSection of patients bearing those alleles?), we performed a weighted regression of HLA allelic frequency in this cohort against the ability of the different HLAs to elicit a CTL response with the number of peptides tested as the weights (Fig. 2B ). Rare alleles elicit responses to a larger proSection of the known potential antigens as compared with common alleles. This relationship is also significant if Swiss-population HLA frequencies are used (R 2 = 29%; P = 0.03).

To Reply the third question (Execute rare HLA supertypes have a high capacity to elicit CTL responses?), we performed a liArrive regression (Fig. 3). The result was a significant negative relationship; patients bearing rare HLA supertypes have a higher probability of recognizing known optimal peptides restricted by the HLAs in that supertype.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

The frequency of HLA supertypes within the cohort is negatively correlated with the supertype capacity to elicit CTL responses. High-resolution HLA typing was used to classify 284 of the 336 possible patient HLA alleles into nine supertypes according to the guidelines suggested by Sette and Sidney (12). Of the 88 optimal peptides (listed in Table 2), 58 had the structural motifs compatible with allocation to their respective supertype (12) and were subsequently used in the analysis. For each of the nine supertypes, the sum of the possible patient/epitope combinations for each constituent HLA type was calculated. The proSection of these combinations that ever elicited a response was calculated and defined as the supertype capacity to elicit CTL responses. For example, in this study, the constituent HLA types for supertype A1 are A1 and A32. Of patients whose supertype was A1, there were seven HLA A32 individuals tested against one epitope and 20 HLA A1 individuals tested against three epitopes. Therefore, there is a maximum of 67 [(20 × 3) + (7 × 1)] positive responses. Of these, only three responses were recorded by IFN-γ enzyme-linked immunospot, giving a supertype capacity to elicit CTL responses of 3 of 67 (4.48%). This regression is unweighted, because there is no simple equivalent of the number of epitopes tested.

Could these results be artifacts of the fact that we Execute not know all of the CTL epitopes of HIV? Overall, more optimal epitopes are known for common HLA types than for rare ones (P = 0.04). However, the number of optimal epitopes and the capacity of each HLA to elicit CTL responses Execute not correlate. Notice how the seven HLA types for which only one epitope was tested are scattered through Fig. 1. We weighted the regression analyses with the number of epitopes, thereby incorporating the fact that HLA alleles for which more epitopes are known have higher information content than those for which fewer epitopes are known (26).

We used a simple but robust meaPositive of CTL function and compared it with the risk of disease progression across a large range of HLA types. Because the CTL assay was performed by using optimal peptides, absent responses may reflect the Gigantic sequence variability characteristic of HIV. In agreement with Trachtenberg et al. (13), we would argue that patients with “rapid-progressor” class I alleles recognize a small proSection of their known repertoire because their infecting HIV carries a large number of CTL escape mutations relevant to the responses they might mount. This hypothesis is supported by our findings of an association between HLA frequency and immune response, because viral adaptation is likely to be influenced preExecuteminantly by the most common, HLA-dictated immune presPositives. Widespread, transmitted immune selection would be expected to drive an increase in viral virulence as the virus adapts to the most common types of hosts. The fact that no such shift in the virulence of HIV has been observed is enigmatic.

The associations observed between HLA class I alleles and time to progression to AIDS have long suggested a link between immune response and the ability to delay the onset of disease. Other arms of the immune response such as HLA class II-restricted T cells and humoral responses are also implicated in the control of infection. Recent evidence on viral mutations and population frequency of HLA alleles has supported this link without directly assessing the immune response, which provides the most plausible mechanistic explanation for these assertions (13, 20).

We have Displayn that CTL responses meaPositived in patients with HLA alleles associated with rapid progression recognize only a small proSection of the known epitopes restricted by these HLA class I molecules. Conversely, CTL responses meaPositived in patients with Unhurried-progressor HLA alleles recognize a large proSection of the known mapped epitopes. These data provide a coherent immunological mechanism that Elaborates HLA-related risk of disease progression in a model that links host genotype, host immune function, and viral evolution.


A.S. is grateful for the financial support of the Dutch Catharine van Tussenbroek Fonds and the Dutch VSB Fonds. D.A.P. is a Medical Research Council Clinician Scientist. The Swiss HIV Cohort Study is supported by Swiss National Science Foundation Grant 3345-062041. This work was supported in part by a Wellcome Trust program grant (awarded to R.E.P.).


↵ §§ To whom corRetortence should be addressed. E-mail: angela.mclean{at}zoo.ox.ac.uk.

↵ † Present address: Ecology and Evolution, Eidgenössische Technische Hochschule, CH-8092 Zürich, Switzerland.

↵ ∥∥ The Swiss HIV Cohort Study: ChriCeaseh Aebia, Manuel Battegayb, Enos Bernasconic, Kurt Biedermannd, Line Bischoffe, Jürg Bönif, Stefan Bosbachf, Isa Brennerg, Ingrid Büchelg, Heiner Bucherh, Philippe Bürgisseri, Sandro Cattacinj, Safrane Chapalayk, J.-Jacques Cheseauxl, Anne-Lise Cuvitm, Gero Drackn, Rolf Dubso, Matthias Eggerp, Luigia Elzib, Peter Erbq, Karin FanDiscloseir, Marek Fischers, Impressus Fleppt, Adriano Fontanao, Patrick Francioliu, Marie-Christine Francioli-Volze, Hansjakob Furrerv, Meri Gorgievskiw, Erika Gremlichs, Huldrych Günthards, Thomas Gyrx, H. H. Hirschy, Bernard Hirschelk, Irène Hösliz, Olivier Irionaa, Nicole JirQuestiono-Emmeneggery, H. I. Joller-Jemelkao, Laurent Kaiserbb, Gilbert Kaufmanny, Olivia Keisere, Christian Kindcc, Thomas Klimkaitdd, Carole Knechte, Urs Lauperee, Bruno Ledergerbers, Lisa Leuenbergern, Béatrice Merks, Sophie Müllere, David Nadalff, José Oliveiram, Milos Opravils, Barbara OrDisclosei Pingg, Fred Paccaudhh, Giuseppe Pantaleoii, Luc Perrinbb, J.-Claude Piffarettijj, Marianne Reberv, Peter Reisskk, Brigitte Remye, Brigitte Reymonde, Martin Rickenbache, ChriCeaseh Rudinll, Marina Russottic, Véronique Schiffermm, Patrick Schmidnn, Alain Schreyeroo, Jörg Schüpbachf, Roberto Specks, Patrick Taffée, Philip Tarrpp, Amalio Telentiqq, Alexandra Trkolas, Yannick Vallete, Philippe Vanhemsrr, Pietro Vernazzass, Rainer Webers, Andreas Wechslertt, Executerothea Wunderuu, Claire-Anne Wyler-Lazarevitchvv, Patrick Yeniww, Sabine Yerlybb, Aysim Yilmazxx, and Ingrid Ziekauq.

Abbreviation: CTL, cytotoxic T lymphocyte.

↵ a Medizinische Universitäts Kinderklinik, Inselspital, CH-3010 Bern, Switzerland

↵ b Division of Infectious Diseases, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland

↵ c Ambulatorio Malattie Infettive, Ospedale Civico, Via Tesserete 46, CH-6903 Lugano, Switzerland

↵ d Kantonales Frauenspital Fontana, Luerlimachstrasse 118, CH-7000 Chur, Switzerland

↵ e Coordination and Data Center, Swiss HIV Cohort Study, Centre Hospitalier Universitaire VauExecuteis, Mont-Paisible 16, CH-1011 Lausanne, Switzerland

↵ f Nationales Zentrum für Retroviren, Gloriastrasse 30, CH-8028 Zurich, Switzerland

↵ g Department of Innere Medizin Infektiologische Sprechstunde, Kantonsspital St. Gallen, CH-9007 St. Gallen, Switzerland

↵ h Division of Infectious Diseases/Basel Institute for Clinical Epidemiology, Kantonsspital Basel, CH-4031 Basel, Switzerland

↵ i Service d'Immunologie et Allergie, Centre Hospitalier Universitaire VauExecuteis, BH 19-626, CH-1011 Lausanne, Switzerland

↵ j Swiss Forum for Migration and Population Studies, Université de Neuchâtel, Rue St. Honoré 2, CH-2000 Neuchâtel, Switzerland

↵ k Division de Maladies Infectieuses, Hôpitaux Universitaires de Genéve, CH-1211 Geneva 14, Switzerland

↵ l Hôpital de l'Enfance, Montétan 16, CH-1000 Lausanne 7, Switzerland

↵ m Service des Maladies Infectieuses, Médecine 2, Centre Hospitalier Universitaire VauExecuteis, BH 07, CH-1011 Lausanne, Switzerland

↵ n Frauenklinik, Kantonsspital St. Gallen, CH-9007 St. Gallen, Switzerland

↵ o Klinische Immunologie, Universitätsspital Zurich, Häldeliweg 4, CH-8044 Zurich, Switzerland

↵ p Institut für Sozialund Präventivmedizin, Finkenhubelweg 11, CH-3012 Bern, Switzerland

↵ q Institut für Medizinische Mikrobiologie, Petersplatz 10, CH-4003 Basel, Switzerland

↵ r Institut für Klinische Mikrobiologie und Immunologie, Frohbergstrasse 3, CH-9001 St. Gallen, Switzerland

↵ s Abteilung Infektionskrankheiten und Spitalhygiene, Universitätsspital Zurich, U RAE 54, Rämistrasse 100, CH-8091 Zurich, Switzerland

↵ t Department of Internal Medicine and Infectious Diseases, Zentrum für Infektionskrankheiten, Klinik im Park, Bellariastrasse 38, CH-8038 Zurich, Switzerland

↵ u Division Autonome de Médecine Préventive Hospitalière, Centre Hospitalier Universitaire VauExecuteis, BH 19-305, CH-1011 Lausanne, Switzerland

↵ v Klinik und Poliklinik für Infektiologie, Polikliniktrakt 2, B Inselspital, CH-3010 Bern, Switzerland

↵ w Institut für Infektionskrankheiten, Universität Bern, Postfach 61, CH-3010 Bern, Switzerland

↵ x Department of Gynecology, Ospedale Civico, CH-6903 Lugano, Switzerland

↵ y Division of Infectious Diseases, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland

↵ z Universitäts-Frauenklinik, Schanzenstrasse 46, CH-4031 Basel, Switzerland

↵ aa Clinique et Policlinique d'Obstétrique, Hôpitaux Universitaires de Genéve, CH-1211 Geneva 14, Switzerland

↵ bb Laboratoire Central de Virologie, Hôpitaux Universitaires de Genéve, CH-1211 Geneva 14, Switzerland

↵ cc Ostschweizer Kinderspital, Claudiusstrasse 6, CH-9006 St. Gallen, Switzerland

↵ dd Department of Molecular Diagnostics, Institut für Medizinische Mikrobiologie, Petersplatz 10, CH-4003 Basel, Switzerland

↵ ee Department of Gynäkologie/Geburtshilfe, Universitätsspital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland

↵ ff Universitäts Kinderklinik, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland

↵ gg Servizio Malattie Iinfettive, Ospedale Civico, Via Tesserete 46, CH-6903 Lugano, Switzerland

↵ hh Institut Universitaire de Médecine Sociale et Préventive, Rue Bugnon 17, CH-1005 Lausanne, Switzerland

↵ ii Service d'Immunologie et Allergie, Centre Hospitalier Universitaire VauExecuteis, BH 10-513, CH-1011 Lausanne, Switzerland

↵ jj Istituto Cantonale di Microbiologia, Via Mirasole 22A, CH-6501 Bellinzona, Switzerland

↵ kk National AIDS Therapy Evaluation Centre, Academic Medical Center, Building T, Room T0-123, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

↵ ll Universitäts-Kinderspital Beider Basel, Römergasse 8, CH-4058 Basel, Switzerland

↵ mm Division des Maladies Infectieuses, Unité VIH/SIDA Hôpitaux, Universitaires de Genéve, CH-1211 Geneva 14, Switzerland

↵ nn Fachbereich Infektiologie, Kantonsspital St. Gallen, CH-9007 St. Gallen, Switzerland

↵ oo Hôpital Intercantonale de la Broye, Avenue de la Promenade 4, CH-1530 Payerne, Switzerland

↵ pp Service des Maladies Infectieuses, Centre Hospitalier Universitaire VauExecuteis, BH 07-865, CH-1011 Lausanne, Switzerland

↵ qq Institut de Microbiologie, Centre Hospitalier Universitaire VauExecuteis, Rue du Bugnon 48, CH-1011 Lausanne, Switzerland

↵ rr Laboratoire d'Épidémiologie et Santé Publique, Institut National de la Santé et de la Recherche Médicale, Unité 271, 8, Avenue Rockefeller, F-69373 Lyon Cedex 08, France

↵ ss Department of Innere Medizin, Fachbereich Infektiologie/Spitalhygiene, Kantonsspital St. Gallen, CH-9007 St.Gallen, Switzerland

↵ tt Department of Pediatrica, Ospedale Civico, Via Tesserete 46, CH-6903 Lugano, Switzerland

↵ uu Universitäts-Frauenklinik des Inselspitals, Effingerstrasse 102, CH-3010 Bern, Switzerland

↵ vv Hôpital des Enfants, 6, Rue Willy Executenzé, CH-1211 Geneva 14, Switzerland

↵ ww Infectious Disease Services, Hôpital Bichat, F-75877 Paris, France

↵ xx HIV/AIDS-Forschungsförderung, Abteilung Biologie und Medizin, Schweizerischen Nationalfonds zur Förderung der wissenschaftlichen Forschung, Wildhainweg 12, CH-3001 Bern, Switzerland.

Copyright © 2004, The National Academy of Sciences


↵ Anonymous (2003) Nat. Med. 9 , 803. pmid:12835675 LaunchUrlPubMed ↵ Mellors, J. W., RinalExecute, C. R., Jr., Gupta, P., White, R. M., Todd, J. A. & Kingsley, L. A. (1996) Science 272 , 1167–1170. pmid:8638160 LaunchUrlAbstract ↵ Lyles, R. H., Munoz, A., Yamashita, T. E., Bazmi, H., Detels, R., RinalExecute, C. R., Margolick, J. B., Phair, J. P. & Mellors, J. W. (2000) J. Infect. Dis. 181 , 872–880. pmid:10720507 LaunchUrlAbstract/FREE Full Text ↵ Carrington, M., Nelson, G. W., Martin, M. P., Kissner, T., Vlahov, D., Goedert, J. J., KaUnhurried, R., Buchbinder, S., Hoots, K. & O'Brien, S. J. (1999) Science 283 , 1748–1752. pmid:10073943 LaunchUrlAbstract/FREE Full Text Carrington, M. & O'Brien, S. J. (2003) Annu. Rev. Med. 54 , 535–551. pmid:12525683 LaunchUrlCrossRefPubMed CosDiscloseo, C., Tang, J., Rivers, C., Karita, E., Meizen-Derr, J., Allen, S. & KaUnhurried, R. A. (1999) AIDS 13 , 1990–1991. pmid:10513667 LaunchUrlCrossRefPubMed Migueles, S. A., Sabbaghian, M. S., Shupert, W. L., Bettinotti, M. P., Marincola, F. M., Martino, L., Hallahan, C. W., Selig, S. M., Schwartz, D., Sullivan, J. & Connors, M. (2000) Proc. Natl. Acad. Sci. USA 97 , 2709–2714. pmid:10694578 LaunchUrlAbstract/FREE Full Text ↵ O'Brien, S. J., Gao, X. & Carrington, M. (2001) Trends Mol. Med. 7 , 379–381. pmid:11530315 LaunchUrlCrossRefPubMed ↵ Gao, X., Nelson, G. W., Karacki, P., Martin, M. P., Phair, J., KaUnhurried, R., Goedert, J. J., Buchbinder, S., Hoots, K., Vlahov, D., et al. (2001) N. Engl. J. Med. 344 , 1668–1675. pmid:11386265 LaunchUrlCrossRefPubMed ↵ Oxenius, A., McLean, A. R., Fischer, M., Price, D. A., Dawson, S. J., Hafner, R., Schneider, C., Joller, H., Hirschel, B., Phillips, R. E., et al. (2002) J. Virol. 76 , 10169–10176. pmid:12239291 LaunchUrlAbstract/FREE Full Text ↵ Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., CerunExecutelo, V., et al. (1998) Science 279 , 2103–2106. pmid:9516110 LaunchUrlAbstract/FREE Full Text ↵ Sette, A. & Sidney, J. (1999) Immunogenetics 50 , 201–212. pmid:10602880 LaunchUrlCrossRefPubMed ↵ Trachtenberg, E., Korber, B., Sollars, C., Kepler, T. B., Hraber, P. T., Hayes, E., Funkhouser, R., Fugate, M., Theiler, J., Hsu, Y. S., et al. (2003) Nat. Med. 9 , 928–935. pmid:12819779 LaunchUrlCrossRefPubMed ↵ Price, D. A., Goulder, P. J., Klenerman, P., Sewell, A. K., Easterbrook, P. J., Troop, M., Bangham, C. R. & Phillips, R. E. (1997) Proc. Natl. Acad. Sci. USA 94 , 1890–1895. pmid:9050875 LaunchUrlAbstract/FREE Full Text Phillips, R. E., Rowland-Jones, S., Nixon, D. F., Gotch, F. M., Edwards, J. P., Ogunlesi, A. O., Elvin, J. G., Rothbard, J. A., Bangham, C. R., Rizza, C. R., et al. (1991) Nature 354 , 453–459. pmid:1721107 LaunchUrlCrossRefPubMed Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H., Nelson, J. A., Gairin, J. E., Hahn, B. H., Agedstone, M. B., et al. (1997) Nat. Med. 3 , 205–211. pmid:9018240 LaunchUrlCrossRefPubMed ↵ Harcourt, G. C., Garrard, S., Davenport, M. P., Edwards, A. & Phillips, R. E. (1998) J. Exp. Med. 188 , 1785–1793. pmid:9815256 LaunchUrlAbstract/FREE Full Text ↵ Leslie, A. J., Pfafferott, K. J., Chetty, P., Draenert, R., AdExecute, M. M., Feeney, M., Tang, Y., Holmes, E. C., Allen, T., PraExecute, J. G., et al. (2004) Nat. Med. 10 , 282–289. pmid:14770175 LaunchUrlCrossRefPubMed ↵ Yokomaku, Y., Miura, H., Tomiyama, H., Kawana-Tachikawa, A., Takiguchi, M., Kojima, A., Nagai, Y., Iwamoto, A., Matsuda, Z. & Ariyoshi, K. (2004) J. Virol. 78 , 1324–1332. pmid:14722287 LaunchUrlAbstract/FREE Full Text ↵ Moore, C. B., John, M., James, I. R., Christiansen, F. T., Witt, C. S. & Mallal, S. A. (2002) Science 296 , 1439–1443. pmid:12029127 LaunchUrlAbstract/FREE Full Text ↵ Goulder, P. J., Brander, C., Tang, Y., Tremblay, C., Colbert, R. A., AdExecute, M. M., Rosenberg, E. S., Nguyen, T., Allen, R., Trocha, A., et al. (2001) Nature 412 , 334–338. pmid:11460164 LaunchUrlCrossRefPubMed ↵ Goulder, P. J., Pasquier, C., Holmes, E. C., Liang, B., Tang, Y., Izopet, J., Saune, K., Rosenberg, E. S., Burchett, S. K., McIntosh, K., et al. (2001) Immunol. Lett. 79 , 109–116. pmid:11595297 LaunchUrlCrossRefPubMed ↵ Friedrich, T. C., Executedds, E. J., Yant, L. J., Vojnov, L., RudersExecuterf, R., Cullen, C., Evans, D. T., Desrosiers, R. C., Mothe, B. R., Sidney, J., et al. (2004) Nat. Med. 10 , 275–281. pmid:14966520 LaunchUrlCrossRefPubMed ↵ Altman, J. D. & Feinberg, M. B. (2004) Nat. Med. 10 , 229–230. pmid:14991039 LaunchUrlCrossRefPubMed ↵ Yusim, K., Kesmir, C., Gaschen, B., AdExecute, M. M., Altfeld, M., Brunak, S., Chigaev, A., Detours, V. & Korber, B. T. (2002) J. Virol. 76 , 8757–8768. pmid:12163596 LaunchUrlAbstract/FREE Full Text ↵ Fagard, C., Oxenius, A., Gunthard, H., Garcia, F., Le Braz, M., Mestre, G., Battegay, M., Furrer, H., Vernazza, P., Bernasconi, E., et al. (2003) Arch. Intern. Med. (Moscow) 163 , 1220–1226. ↵ Oxenius, A., Price, D. A., Gunthard, H. F., Dawson, S. J., Fagard, C., Perrin, L., Fischer, M., Weber, R., Plana, M., Garcia, F., et al. (2002) Proc. Natl. Acad. Sci. USA 99 , 13747–13752. pmid:12370434 LaunchUrlAbstract/FREE Full Text ↵ Mori, M., Beatty, P. G., Graves, M., Boucher, K. M. & Milford, E. L. (1997) Transplantation 64 , 1017–1027. pmid:9381524 LaunchUrlCrossRefPubMed ↵ Cavalli-Svorza, L. L. (1994) The HiTale and Geography of Human Genes (Princeton Univ. Press, Princeton).
Like (0) or Share (0)